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ABSTRACT
The coronavirus disease-2019 (COVID-19) pandemic has strained health care resources around the world, causing many
institutions to curtail or stop elective procedures. This has resulted in an inability to care for patients with valvular and
structural heart disease in a timely fashion, potentially placing these patients at increased risk for adverse cardiovascular
complications, including CHF and death. The effective triage of these patients has become challenging in the current
environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during
the COVID-19 pandemic against the risk of delaying a needed procedure. In this document, the authors suggest guidelines
for how to triage patients in need of structural heart disease interventions and provide a framework for how to decide
when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, the authors address
the triage of patients in need of transcatheter aortic valve replacement and percutaneous mitral valve repair. The authors
also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19
pandemic. (J Am Coll Cardiol Intv 2020;13:1484–8) © 2020 by the American College of Cardiology Foundation.
ISSN 1936-8798/$36.00 https://doi.org/10.1016/j.jcin.2020.04.001
This paper is being published simultaneously in Catheterization and Cardiovascular Interventions and JACC: Cardiovascular
Interventions.
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T he coronavirus disease-2019 (COVID-19)pandemic has put an enormous strain onhealth care systems worldwide. Hospitals in
China, Italy, Spain, and now the United States have
experienced surges of critically ill patients with
COVID-19, which has resulted in a dramatic depletion
of hospital resources, infection of health care
personnel, and critical shortages of vital resources,
including personal protective equipment (PPE), ven-
tilators, and intensive care unit (ICU) beds. Capacity
has also become limited to provide care for patients
with serious comorbid conditions in need of urgent
care not related to COVID-19. To preserve PPE and
prepare for the potential surge of COVID-19 patients
to U.S. hospitals, the Centers for Medicare and
Medicaid Services has asked for deferral of nonessen-
tial procedures and operations (1). Patients who are in
need of structural heart disease (SHD) intervention
constitute a particularly challenging group, as many
of them have conditions that may be life threatening
if intervention is inappropriately delayed. Therefore,
decisions regarding the timing of SHD interventions
must consider the risk of delaying the procedure,
the risk for the patient of COVID-19 exposure outside
of home shelter, and use of limited hospital resources.
Compounding this challenge is the geographic varia-
tion in the peak of the pandemic within the United
States and the significant delay in restoration of
normal health care operations after the immediate
threat has passed. The length of this delay is un-
known but could be many months subsequent to the
peak, which poses distinct challenges for reschedul-
ing procedures. The purpose of this document is to
provide a framework for SHD teams to triage patients
in need of SHD intervention during the COVID-19
pandemic and to discuss evaluation and procedural
considerations for these patients.
The general priorities are: 1) to minimize exposure
to coronavirus for patients with SHD and
the structural interventional team; 2) to maintain
high-quality and durable structural inter-
ventional outcomes in those who do
require procedures during the pandemic;
3) to reduce the risk that these patients with
SHD use resources that might be needed for
patients with COVID-19; and 4) to prevent
delay of intervention in patients at particu-
larly high risk for clinical deterioration, heart
failure, and death. It is understood that for
any individual patient, local clinical judg-
ment based on the impact of the COVID-19
pandemic in the region and institution
should ultimately guide the evaluation and
treatment pathway.
TRANSCATHETER AORTIC
VALVE REPLACEMENT
Given advanced age and comorbidities, many pa-
tients with severe symptomatic aortic stenosis (AS)
are at increased risk for COVID-19 complications and
death. However, multiple studies have also shown
higher mortality among patients with severe symp-
tomatic AS with a delay in treatment (2,3) over several
months to years rather than weeks.
This writing group proposes the following for the
timing of transcatheter aortic valve replacement
(TAVR) for patients with severe AS during the
COVID-19 pandemic.
SYMPTOMATIC SEVERE AS. For inpatients with se-
vere symptomatic AS associated with a reduction in
ejection fraction thought to be secondary to AS,
presence of New York Heart Association functional
class III or IV congestive heart failure (CHF), or syn-
cope secondary to AS, TAVR should be considered to
decrease the risk for clinical deterioration, prolonged
hospital stay, or repeat hospitalization. It would be
reasonable to schedule TAVR for outpatients with
severe to critical AS and class III or IV CHF symptoms
or syncope due to AS.
AB BR EV I A T I O N S
AND ACRONYM S
CHF = congestive heart failure
COVID-19 = coronavirus
disease-2019
ICU = intensive care unit
MR = mitral regurgitation
PPE = personal protective
equipment
SHD = structural heart disease
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
TMVR = transcatheter mitral
valve replacement
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MINIMALLY SYMPTOMATIC SEVERE TO CRITICAL AS.
For patients with New York Heart Association func-
tional class I or II CHF symptoms and quantitative
measures of valve severity that indicate a critically
tight valve, it is reasonable to consider either urgent
TAVR or close outpatient virtual monitoring by the
valve coordinator. Data to date are not robust
enough to give firm recommendations, but features
that warrant consideration of TAVR include partic-
ularly high peak or mean gradient, very small
calculated aortic valve area, and very low dimen-
sionless index.
ASYMPTOMATIC SEVERE TO CRITICAL AS. For truly
asymptomatic patients, it is reasonable to postpone
consideration of TAVR for 3 months or until after
hospital operations resume elective procedures. Close
outpatient monitoring, possibly via telehealth,
should continue for all patients with severe AS.
TAVR centers should establish a system that pro-
vides weekly telephone follow-up for patients whose
procedures have been deferred. It is expected that
some of these patients will develop worsening of their
symptoms and will require the procedure to be per-
formed more urgently during the pandemic. We
recommend that the TAVR team convene virtually on
at least a weekly basis to review the status of patients
on the “waiting” list. A single interventional cardiol-
ogist and cardiac surgeon should assume a leadership
position and be given the authority to arbitrate chal-
lenging cases. No triage system can accurately identify
all patients who may be safely deferred; the triage
system will need to be individualized to each medical
center, institutional valve program, and patient pop-
ulation served, as well as the pandemic’s local impact.
PROCEDURAL CONSIDERATIONS FOR TAVR DURING
THE COVID-19 PANDEMIC. There should be no
compromise in the quality of interventional care
provided to TAVR patients during the COVID-19
pandemic. The majority of TAVR procedures can be
performed using a minimalist approach, with mod-
erate conscious sedation. Recent data from the TVT
(Transcatheter Valve Therapy) Registry have shown a
steady increase in the use of moderate sedation for
TAVR, with improved safety and recovery (4,5). The
majority of TAVR procedures do not require ICU re-
covery after the procedure, and this is important as
critical care beds will be limited during the COVID-19
crisis in parts of the country. Percutaneous coronary
intervention should be performed prior to TAVR only
when coronary artery disease is contributing to the
patient’s clinical presentation or would pose high risk
for the TAVR procedure. Otherwise, percutaneous
coronary intervention may be safely deferred (6,7).
TRANSCATHETER MITRAL VALVE PROCEDURES
PERCUTANEOUS MITRAL VALVE REPAIR. The ma-
jority of percutaneous mitral valve repair (edge-to-
edge repair) can be safely deferred. The following
groups of patients should be considered for treat-
ment with edge-to-edge repair during the COVID-19
pandemic: 1) inpatients with severe functional
mitral regurgitation (MR) (3þ/4þ) who cannot be
safely discharged despite optimized guideline-
directed medical therapy by a heart failure
specialist; 2) outpatients with severe functional MR
(3þ/4þ) with hospitalization for CHF within 30 days
despite optimized guideline-directed medical ther-
apy by a heart failure specialist; 3) inpatients with
CHF and severe degenerative MR (3þ/4þ) due to
acute valvular dysfunction (i.e., secondary to
ruptured chord or papillary muscle rupture after
myocardial infarction) who are at high risk for sur-
gical mitral valve repair or replacement; 4) out-
patients with severe degenerative MR (3þ/4þ) with
hospitalization within 30 days despite optimized
medical therapy who are high risk for surgical mitral
valve repair or replacement; and 5) patients with
either severe degenerative MR or functional MR who
are in low-output, decompensated heart failure
requiring ICU-level care for whom edge-to-edge de-
vice implantation might improve hemodynamic sta-
tus for extubation and/or transfer out of the
ICU setting.
It is the responsibility of the procedural team
to keep in contact with patients who are
deferred on a weekly basis to ensure that there
has been no decompensation requiring earlier
intervention.
VALVE-IN VALVE TRANSCATHETER MITRAL VALVE
REPLACEMENT (TMVR). Valve-in-valve TMVR is the
only other transcatheter mitral valve intervention
that is currently approved by the U.S. Food and Drug
Administration. Because these procedures are
resource intensive, they should be deferred until af-
ter the COVID-19 pandemic has adequately resolved,
provided such mitral valve patients can be suffi-
ciently managed on medical therapy in the interim.
Valve-in-valve TMVR during the COVID-19 pandemic
should be considered for patients with severe bio-
prosthetic mitral stenosis or MR who are inpatients
with CHF or outpatients who have had hospitaliza-
tions for CHF within 30 days despite optimized
guideline-directed medical therapy. Valve-in-ring
TMVR and valve–in–mitral annular calcification
TMVR are off-label procedures and pose much
higher risk for complications that may prolong
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hospitalization (8,9). These latter procedures
should be generally avoided during the COVID-
19 pandemic.
PARAVALVULAR LEAK CLOSURE
Paravalvular leak closure (particularly mitral) is
generally a lengthy procedure and requires general
anesthesia and transesophageal echocardiography
(TEE). Patients with significant paravalvular leaks but
with symptoms that can be managed medically
should be deferred until after the moratorium on
nonessential procedures has been removed. Patients
who should be considered for paravalvular leak
closure during the COVID-19 pandemic are inpatients
with CHF and/or hemolysis.
OTHER SHD INTERVENTIONS
Other commonly performed SHD interventions
include patent foramen ovale closure, atrial septal
defect closure, left atrial appendage occlusion, and
alcohol septal ablation for hypertrophic cardiomyop-
athy. These procedures treat conditions that rarely
result in hospitalization or death without the pro-
cedure over the short term. For these reasons, these
procedures should be deferred until it is deemed safe
to resume performing nonemergent procedures in
procedural suites.
INTRAPROCEDURAL IMAGING CONSIDERATIONS
To offset the risk for particulate aerosolization, pre-
procedural TEE should be limited in use. If a patient
is planned for an emergent percutaneous mitral valve
repair procedure, on-table TEE will suffice in case
planning at experienced centers. For any high-risk
SHD procedure requiring interventional imaging
support with TEE, emphasis must be placed on the
availability of full PPE for the interventional imager.
The major aerosolization risk to the interventional
imager and cardiac anesthesia team occurs during the
initial intubation and any transesophageal probe
manipulation thereafter in a nonintubated patient. In
an already ventilated patient, care should be made
that a high-efficiency particulate air filter is placed
with the endotracheal tube to maximize safety of the
SHD team at the head of the patient’s bed. In the
absence of sufficient PPE, alternative imaging
modalities should be considered (intracardiac echo-
cardiography if possible), as there is high risk for
COVID-19 exposure with performance of TEE.
OUTPATIENT CLINICS
The SHD clinic is a vital entry point for patients with
valvular heart disease and SHD into the health care
system. In preparation for a procedure, patients
require visits with multiple physicians and additional
visits for imaging. Having patients make multiple
trips to the hospital should be avoided during the
COVID-19 pandemic to minimize the risk for virus
transmission among inpatients, outpatients, and
health care personnel. The SHD clinic should help
coordinate visits for patients with SHD, and efforts
should be made to use telemedicine for consultations.
If a patient requires treatment during the COVID-19
pandemic, pre-procedural visits and imaging should
be consolidated to a single hospital encounter prior to
the procedure if possible. It will be important to
maintain typical SHD clinic volumes with virtual
visits during the pandemic so that preparations can
be made to treat patients in need of SHD intervention
as soon as possible once normal hospital operations
are restored. Recently, the Society of Thoracic Sur-
geons/American College of Cardiology TVT Registry
allowed the substitution of in-person visits with
telephone or virtual visits for the 30-day and 1-year
follow-up visits. Although some elements of these
registries cannot be collected with remote follow-up,
this will need to be addressed at a future date.
SHD TEAM PERSONNEL
SHD clinics and procedures are sustained through a
multidisciplinary heart team process. This team con-
sists of interventional cardiologists, cardiac surgeons,
cardiac imaging specialists, anesthesiologists, and
nurse specialists. Depending on the work flows and
potential exposure both within the hospital (as rates
of exposure-based infections to health care workers
remain high during this pandemic) and outside the
workplace, team members may need to be quaran-
tined or treated for illness. This may lead to in-
terruptions in scheduled cases depending on the
length of absence. Consideration of clustered sched-
uling using designated teams may be helpful in
addressing interruptions due to temporary absence of
team personnel.
CLINICAL TRIALS
Strong consideration should be given for deferral of
all clinical trial cases until after adequate resolution
of the COVID-19 pandemic. This recommendation
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should also be determined in accordance with insti-
tutional research policies, as several institutions have
limited enrollment in clinical trials to only studies of
lifesaving therapies during the pandemic. If patients
being considered for clinical investigation become
clinically unstable during the COVID-19 pandemic,
they should be treated using commercially approved
therapies. Continued follow-up of patients already
enrolled and treated should be maintained.
CONCLUSIONS
The present COVID-19 pandemic has led heart teams
to reprioritize many SHD interventions considering
the ongoing surge of other critically ill patients. The
current pandemic will require physicians to make
challenging decisions regarding the proper triage
and deferral of patients as necessary. There remains
significant uncertainty regarding the trajectory of
the COVID-19 pandemic, but on the basis of the
experience of other nations, the U.S. health care
system must be prepared for a surge of critically ill
patients in the coming weeks. A coordinated multi-
disciplinary effort needs to occur to safely defer and
monitor patients with SHD requiring interventional
therapies.
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